System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Prof Laure Michel is an expert in Neurology at Centre Hospitalier Universitaire de Rennes (France). As of October 2026, ScienceLeadR ranks Laure Michel in the top 1% of experts worldwide for Multiple Sclerosis and Autoimmune Diseases. Laure Michel has authored 146 publications, the most recent in 2026, and is an investigator in 28 clinical trials, 12 of them ongoing. SLR score: 1,218 (community average: 125). How the SLR is computed.

LeadR Profile

Prof Laure Michel Centre Hospitalier Universitaire de Rennes France
1 218 ScienceLeadR Reputation 1218

Unlock

Register Login
Network Map

Neurology

Subspecialties: Immunology - Neurosurgery - Psychiatry

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2008 - 2026
Source: PubMed

INSERM

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 146

Citations

Citations: 3 484 1st author: 20 Last author: 17 Unique author: 5

Main journals

Neurology 17
Rev Neurol (Paris) 13
Mult Scler 11
Elsevier eBooks 8
Mult Scler Relat Disord 7

Best Journals

Circulation 1
Immunity 1
JAMA 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Serum GFAP and Age Accurately Distinguish AQP4-IgG Positive and Double Seronegative NMOSD From MOGAD After a Recent Attack.
PMID 42798289 — multiple sclerosis, serum, probability, biomarkers, neuromyelitis optica, diagnosis, nervous system diseases		Eur J Neurol20260
Anti-CD20 Discontinuation Versus Continuation in People Aged Over 50 With Non-Active Multiple Sclerosis.
PMID 42596034 — sclerosis, multiple sclerosis, aged, therapeutics, nervous system diseases, infections		Ann Clin Transl Neurol20260
Blood cytotoxic natural killer-like CD8 + CD94+ T cells migrate to the brain and predict multiple sclerosis severity.
PMID 42377966 — cells, sclerosis, multiple sclerosis, blood, lymphocytes, brain, adaptive immunity, wounds and injuries, neurology, immunology		Brain20260
A predictive tool for early treatment escalation after initiation of moderate-efficacy therapy in pediatric-onset multiple sclerosis.
PMID 42226562 — registries, sclerosis, multiple sclerosis, central nervous system diseases, adolescent, therapeutics, child		Mult Scler20260
French NOMADMUS Cohort Overview: Landscape Evolution of AQP4+NMOSD and MOGAD From 2010 to 2024.
PMID 42172556 — neuromyelitis optica, therapeutics, neurology		Neurology20260

Clinical Studies 28

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 13

By phase:

Phase 3 12
N/A 10
Phase 1 2
Phase 2 2
Phase 4 2

By status:

Completed 11
Recruiting 10
Active not recruiting 3
Not yet recruiting 2
Unknown 2

By type:

Interventional 21
Observational 7

By Monocentric/Multicentric:

monocentric 5
multicentric2to4 2
multicentric5to9 2
multicentricup10 19

Main Topics

Cohort/Consortium Investigators 2

Ongoing Clinical Trials

12 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A study to investigate long term safety and tolerability of tolebrutinib in participants with multiple sclerosis
2023-503631-18-01 — sclerosis, multiple sclerosis, safety, nervous system, nervous system diseases, primary progressive multiple sclerosis, secondary progressive multiple sclerosis		Phase 3Active not recruiting2024
A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosis
2025-521546-23-00 — sclerosis, multiple sclerosis, safety, secondary progressive multiple sclerosis		Phase 3Recruiting2026
LONG TERM EFFECTIVENESS AND SAFETY EVALUATION OF OCRELIZUMAB IN FRENCH PATIENTS WITH PROGRESSIVE MS CONSONANCE EXTENSION STUDY
2024-516433-13-00 — safety		Phase 3Recruiting2024
MAESTRO 4MS Allogenic Adipose tissue derived Mesenchymal Stromal Cells for the treatment of Primary Progressive Multiple Sclerosis an open label phase I clinical trial
2023-509538-20-01 — clinical trials, phase i as topic, cells, sclerosis, multiple sclerosis, mesenchymal stem cells, therapeutics, stromal cells, tissues, adipose tissue, primary progressive multiple sclerosis		Phase 1Recruiting2025
DESIRE MS A prospective randomized non inferiority trial comparing anti CD20 maintenance versus De Escalation Strategy In Relapsing Remitting Multiple Sclerosis
2024-513292-40-00 — sclerosis, multiple sclerosis, maintenance, therapeutics, random allocation, multiple sclerosis, relapsing-remitting		Phase 3Recruiting2026

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS